3/26
09:40 am
maze
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Medium
Report
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
3/25
01:51 pm
maze
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
Medium
Report
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
3/25
11:17 am
maze
Maze Therapeutics (MAZE) had its price target raised by HC Wainwright from $60.00 to $110.00. They now have a "buy" rating on the stock.
Medium
Report
Maze Therapeutics (MAZE) had its price target raised by HC Wainwright from $60.00 to $110.00. They now have a "buy" rating on the stock.
3/25
07:00 am
maze
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
High
Report
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
3/25
07:00 am
maze
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
High
Report
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
3/21
10:40 pm
maze
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears [Yahoo! Finance]
Low
Report
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears [Yahoo! Finance]
3/19
06:20 am
maze
Maze Therapeutics (MAZE) was upgraded by Truist Financial Corporation to "strong-buy".
Low
Report
Maze Therapeutics (MAZE) was upgraded by Truist Financial Corporation to "strong-buy".
3/17
07:03 pm
maze
Maze Therapeutics (MAZE) was given a new $68.00 price target by Truist Financial Corporation.
Medium
Report
Maze Therapeutics (MAZE) was given a new $68.00 price target by Truist Financial Corporation.
3/16
08:43 am
maze
Maze Therapeutics (MAZE) had its price target raised by Wedbush from $43.00 to $58.00. They now have an "outperform" rating on the stock.
Low
Report
Maze Therapeutics (MAZE) had its price target raised by Wedbush from $43.00 to $58.00. They now have an "outperform" rating on the stock.
3/13
06:18 am
maze
Maze Therapeutics (MAZE) was upgraded by Mizuho to "strong-buy".
Medium
Report
Maze Therapeutics (MAZE) was upgraded by Mizuho to "strong-buy".
3/10
08:03 am
maze
Maze Therapeutics (MAZE) is now covered by Mizuho. They set an "outperform" rating and a $97.00 price target on the stock.
High
Report
Maze Therapeutics (MAZE) is now covered by Mizuho. They set an "outperform" rating and a $97.00 price target on the stock.
3/9
08:03 am
maze
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
Low
Report
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
3/4
08:44 am
maze
Maze Therapeutics (MAZE) had its price target raised by Guggenheim from $46.00 to $58.00. They now have a "buy" rating on the stock.
Low
Report
Maze Therapeutics (MAZE) had its price target raised by Guggenheim from $46.00 to $58.00. They now have a "buy" rating on the stock.
2/25
07:00 am
maze
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Low
Report
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
2/16
02:12 am
maze
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge [Yahoo! Finance]
Low
Report
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge [Yahoo! Finance]
2/14
07:51 pm
maze
Maze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return [Yahoo! Finance]
Low
Report
Maze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return [Yahoo! Finance]
2/7
02:07 am
maze
Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at
Wall Stree
Medium
Report
Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at
Wall Stree
2/4
07:00 am
maze
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Low
Report
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
2/1
07:03 pm
maze
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock [Yahoo! Finance]
Medium
Report
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock [Yahoo! Finance]
1/28
10:12 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/25
03:05 am
maze
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at
Wall Street
Low
Report
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at
Wall Street
1/17
01:11 am
maze
Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at
Wall Stree
Medium
Report
Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at
Wall Stree
1/16
12:28 pm
maze
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at BTIG Research from $37.00 to $46.00. They now have a "buy" rating on the stock.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at BTIG Research from $37.00 to $46.00. They now have a "buy" rating on the stock.
1/16
03:48 am
maze
Maze Therapeutics: An Innovative, Nature-Driven Platform [Seeking Alpha]
Low
Report
Maze Therapeutics: An Innovative, Nature-Driven Platform [Seeking Alpha]
1/9
07:16 am
maze
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% [Yahoo! Finance]
Medium
Report
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% [Yahoo! Finance]